Related Experiment Video

Updated: Apr 28, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib

Jun-Li Liang1, Xiao-Cang Ren2, Qiang Lin2

  • 1Department of Radiation Oncology, Hebei Medical University Fourth Hospital, Shijiazhuang, People's Republic of China.

Oncotargets and Therapy
|May 31, 2014
PubMed

Insights

Icotinib hydrochloride, a Chinese-developed tyrosine kinase inhibitor, shows efficacy comparable to gefitinib in advanced non-small-cell lung cancer (NSCLC) patients. This oral medication is now a key treatment option for NSCLC in China.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor developed in China.
  • It holds independent intellectual property rights within the People's Republic of China.

Purpose of the Study:

  • To present the Phase I, II, and III clinical trials of icotinib.
  • To discuss the current clinical applications and future research directions for icotinib in China.

Main Methods:

  • Review of Phase I, II, and III clinical trial data for icotinib.
  • Analysis of clinical usage data and outcomes in advanced non-small-cell lung cancer (NSCLC) patients.

Main Results:

  • Clinical trials demonstrated that icotinib's response rate in advanced NSCLC patients (post-platinum-based chemotherapy) was not inferior to gefitinib.
  • Icotinib has been widely adopted in clinical practice in China since its launch in August 2011.

Conclusions:

  • Icotinib is an important treatment option for Chinese patients with advanced NSCLC.
  • Further research is warranted to explore future directions and optimize icotinib's clinical application.
Keywords:
EGFR-TKINSCLCtargeted therapy

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689